Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Atacicept→

Atacicept Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
845264-92-8
Molecular formula
C3104H4788N856O950S44
Molecular weight
70708.13 g/mol
Drug class
TACI-Fc fusion proteindual B-lymphocyte stimulator (BLyS/BAFF) and APRIL inhibitor biologic
Mechanism of action
A soluble fusion protein comprising the extracellular domain of TACI linked to an Fc region. It binds and neutralises BLyS (BAFF) and APRIL, reducing survival and activation signals for B cells and antibody-producing plasma cells.
Indications / reported uses
  • Reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression under the US FDA accelerated approval for atacicept-vymj (Trutakna, initial approval 2026). Long-term effect on kidney-function decline was not established in the accelerated-approval label; consult current product information.

Sources: US DailyMed — TRUTAKNA prescribing information, updated July 6 2026 · US FDA label — TRUTAKNA · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Atacicept Environmental Risk Assessment (ERA) (the Atacicept ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.